Article Sidebar

Date Published: 19/12/2024
Abstract Views: 27
DOI: 10.52322/jocmbmh.143.0214
Issue
Vol. 2 No. 143 (2024)
Section
How to papers
How to Cite
Kieu Thi Van, O., Phan Thi, P., Tran Thi Thu, T., & Nguyen Hoang, Y. (2024). FACTORS ASSOCIATED WITH ADHERENCE TO TYROSINE KINASE INHIBITOR THERAPY IN CHRONIC MYELOID LEUKEMIA. Journal of Clinical Medicine Bach Mai Hospital, 2(143), 103-110. https://doi.org/10.52322/jocmbmh.143.0214

FACTORS ASSOCIATED WITH ADHERENCE TO TYROSINE KINASE INHIBITOR THERAPY IN CHRONIC MYELOID LEUKEMIA

Oanh Kieu Thi Van1, , Phuong Phan Thi1, Thuy Tran Thi Thu1, Yen Nguyen Hoang1
1 Trung tâm Huyết học và Truyền máu, Bệnh viện Bạch Mai

Author contact

  • Contact information: Oanh Kieu Thi Van
  • Email: vanoanh.hhbm@gmail.com
  • Address: Trung tâm Huyết học và Truyền máu, Bệnh viện Bạch Mai

Main Article Content

Abstract

Objective: Determine factors affecting treatment adherence of patients with chronic myeloid leukemia who are being treated with tyrosine kinase inhibitors at Bach Mai Hospital. Participants and Methods: Cross-sectional study on 144 patients with chronic myeloid leukemia treated at Bach Mai Hospital from April 2023 to April 2024. Results: Mean age was 57.46 ± 13.6 years, with the 35-60 age group comprising 57.6%. 42.1% had unstable employment. 40% had income < 5 million VND/month, and 40.3% had 5-10 million VND/month. Medication adherence > 80% was achieved by 76.4%, and overall treatment adherence was 75%. Education level and income significantly affected patient adherence to medication and treatment. Conclusion: Adherence to TKI treatment is crucial for CML patient outcomes. Education level and income significantly affect treatment adherence.

Keywords

Chronic myelogenous leukemia (CML), Tyrosine kinase inhibitor (TKI), adherence

Article Details

References

1. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917-927.
2. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
3. Kekäle M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M. Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence. 2014;8:1619-1627.
4. Tan BK, Tan SB, Chen LC, et al. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adherence. 2017;11:1027-1034.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 1.2023. 2022.
6. Lee PM, Chong CT. Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital. Int J Clin Pharm. 2021;43:46-54.
7. Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87(7):687-691.
8. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
9. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471-474.